



**Contact:**

Douglas Kolodny-Hirsch, Ph.D., M.B.A.  
Senior Director, Business Development  
MaxCyte, Inc.  
(301) 944-1700

**For Immediate Release**

**MaxCyte To Present at BIOTECH CHINA 2007**

Gaithersburg, MD, June 20, 2007 – MaxCyte, Inc., a clinical stage therapeutics company and pioneer in clinical scale, non-viral cell loading systems, announces Douglas M. Kolodny-Hirsch, Ph.D., Senior Director Business Development, will be presenting at the BIOTECH CHINA 2007, Shanghai International Exhibition Center, Shanghai, China on Wednesday, July 4, 2007 at 1:30 pm.

Dr. Kolodny-Hirsch's presentation entitled "Engineered Cellular Therapeutics Using Scaleable Manufacturing Processes," will provide an overview of MaxCyte's approach to customizing and augmenting biological activity of cellular products and their implementation, utilizing the company's proprietary technology platform, into robust, scalable, cGMP-compliant manufacturing processes for clinical and commercial delivery.

**About MaxCyte**

MaxCyte is a clinical-stage cell therapeutics company with a rapidly growing pipeline of product development partnerships in cell-based therapies. The Company's proprietary *ex vivo* cell loading technology overcomes critical obstacles such as safety, scalability and reproducibility which are fundamental to successful cell-based therapies. MaxCyte has demonstrated the value of its versatile technology in partnered therapeutic programs in oncology, pulmonary, metabolic and infectious diseases as well as in development collaborations with leading researchers. Current clinical programs with MaxCyte-engineered cells include: a Phase I/II clinical study for treatment of chronic lymphocytic leukemia (CLL) and a Phase IIa study using engineered stem cells for the treatment of primary Pulmonary Arterial Hypertension (PAH). In addition there are advanced preclinical programs in oncology and regenerative medicine. More than 16 commercial and academic partners are currently using the MaxCyte technology. The MaxCyte system has an FDA Master File in place at CBER.

**For more information, visit <http://www.maxcyte.com>.**

*This press release may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties.*

###